GLP-1 Incretin Research — Semaglutide, Tirzepatide, Retatrutide Compared
The incretin agonist class has expanded rapidly in metabolic research over the past five years. What began with single GLP-1 receptor agonists like Semaglutide has progressed to dual-receptor compounds like Tirzepatide (GIP + GLP-1) and now to triple-receptor compounds like Retatrutide (GLP-1 + GIP + glucagon). Each receptor added to the molecular profile changes the downstream metabolic signature in ways that matter for any researcher choosing among these compounds.
This comparison walks through the three flagship incretin peptides at the receptor-pharmacology level and explains what each receptor contributes. It is intended for researchers and is not medical advice.
The receptors at a glance
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| GLP-1 receptor | ✓ (primary) | ✓ (balanced) | ✓ (balanced) |
| GIP receptor | — | ✓ (GIP-biased) | ✓ |
| Glucagon receptor | — | — | ✓ |
| Class | Single agonist | Dual co-agonist | Triple agonist |
| Half-life (research) | ~7 days (weekly) | ~5 days (weekly) | ~6 days (weekly) |
| Albumin binding | Fatty-acid side chain | Fatty-acid side chain | Fatty-acid side chain |
| Sequence length | 31 aa | 39 aa | ~39 aa |
What each receptor contributes
GLP-1 receptor (all three)
The GLP-1 receptor is the foundation of the class. Activation drives glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon secretion, slows gastric emptying, and engages central satiety signalling at the hypothalamus and area postrema. Every compound in this class engages GLP-1R, and most of the appetite/satiety signal comes from this receptor.
GIP receptor (Tirzepatide and Retatrutide)
Adding the GIP receptor changes the picture. GIP is the second incretin hormone — it amplifies post-prandial insulin secretion and has additional effects on adipose-tissue lipid handling and bone metabolism. Tirzepatide is GIP-biased (higher affinity at GIPR than GLP-1R), which contributes to its measured difference in metabolic profile compared with single GLP-1 agonists.
Glucagon receptor (Retatrutide only)
Adding the glucagon receptor is what makes Retatrutide structurally distinct. Glucagon receptor activation drives hepatic glucose output (a hyperglycaemic signal in isolation) and increases energy expenditure through hepatic and brown-adipose-tissue thermogenesis. The trick of Retatrutide is balancing the glucagon arm (which raises glucose) against the GLP-1 + GIP insulinotropic arms (which lower glucose) so the net glycaemic effect is favourable while energy expenditure climbs. This is why Retatrutide research is associated with metabolic outcomes that go beyond what dual-agonist compounds achieve.
How the three compounds compare in research
Across published clinical-research data, the three compounds differ along three axes:
- Body weight effect (research outcomes): Single GLP-1 (Sema) < Dual GIP/GLP-1 (Tirz) < Triple GLP-1/GIP/glucagon (Reta). The progression tracks the addition of receptor arms.
- Glycaemic control: All three compounds achieve clinically meaningful HbA1c reductions in research populations, with the dual and triple agonists reporting larger effects.
- Energy expenditure: Sema and Tirz are appetite-and-insulin-driven (lower intake, better glucose handling). Retatrutide adds a metabolic-rate dimension via the glucagon arm. The energy-expenditure profile is what distinguishes triple agonism mechanistically.
For comparative metabolic research, the choice depends on the question: a single GLP-1 agonist is the cleanest probe for GLP-1R-specific effects; dual or triple agonists are better for whole-axis incretin/glucagon studies.
Where the amylin axis fits in
A fourth path that runs alongside the incretin family is the amylin axis. Cagrilintide is a long-acting amylin analogue that engages the amylin receptor for satiety, slowed gastric emptying, and post-meal glucose excursion. Combining it with a GLP-1 agonist gives CagriSema — orthogonal mechanisms, additive effects. This is a different design philosophy than triple agonism: instead of stacking incretin arms in one molecule, CagriSema stacks two unrelated receptor families.
Choosing for a research question
| Research question | Best-fit compound |
|---|---|
| GLP-1 receptor pharmacology specifically | Semaglutide |
| GIP-receptor contribution / dual-incretin pharmacology | Tirzepatide |
| Glucagon-receptor contribution / triple-incretin pharmacology | Retatrutide |
| Amylin + GLP-1 axis combined | CagriSema |
| Glucagon + GLP-1 dual | Survodutide |
Pitfalls to avoid in research designs
- Treating "GLP-1 class" as a monolith. Single, dual, and triple agonists are mechanistically distinct. A finding with one doesn't replicate with another by default.
- Conflating effect magnitude with mechanism. Retatrutide's larger effects in research aren't because it's a "stronger GLP-1 agonist" — they're because it engages a different set of receptors. Mechanism studies need single-agonist comparisons.
- Ignoring half-life when comparing. All three are weekly compounds, but half-lives differ enough that dosing schedules in research need explicit per-compound design.
- Assuming GIP-bias = GIP-only. Tirzepatide is GIP-biased in receptor affinity, but it still meaningfully engages GLP-1R. The bias is relative, not absolute.
Suppliers
Aether Bio supplies Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, CagriSema, and Survodutide for laboratory research applications. Same-day dispatch from Indonesia-based stock.
For laboratory research applications only. Not for human consumption. Baca dalam Bahasa Indonesia.